Advertisement
LMAT vs SYK
Which Stock Would AI Choose? LeMaitre Vascular (LMAT) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- LMAT has delivered a standout year-to-date return of approximately 28% in 2026, driven by consistent double-digit revenue growth, expanding margins, and a robust cash position exceeding $340 million.
- SYK is navigating a more challenging 2026, with its stock essentially flat year-to-date and trading roughly 13% below its 52-week high, partly due to an operational disruption from a cyberattack in the first quarter.
- LeMaitre Vascular and Stryker operate at dramatically different scales — LMAT is a $2.4 billion niche vascular device specialist, while Stryker is a $135 billion diversified MedTech giant with $25 billion in annual revenue.
- Both companies posted double-digit organic sales growth in recent quarters, yet their stock price trajectories have diverged meaningfully in 2026, reflecting contrasting market sentiment and risk profiles.
- Stryker's broader portfolio and massive installed base provide defensive resilience, while LeMaitre's focused product lineup and lean operating model have enabled superior margin expansion and faster earnings growth in the current cycle.
- AI-driven trend analysis currently favors LMAT based on momentum consistency and relative stability, though Stryker's scale and diversification warrant continued attention from long-term investors.
Introduction
Medical technology stocks have long been a cornerstone of growth-oriented portfolios, and comparing two companies at opposite ends of the size spectrum — LeMaitre Vascular (LMAT) and Stryker (SYK) — offers a revealing lens into how market dynamics, operational execution, and investor sentiment interact. LMAT is a focused, small-cap vascular device manufacturer with a market capitalization near $2.4 billion. Stryker, by contrast, is one of the world's largest MedTech companies, valued at approximately $135 billion. This comparison is relevant for investors weighing concentrated niche growth against diversified healthcare exposure, as well as for traders evaluating relative momentum and trend consistency in the current market environment.
LMAT Overview and Recent Performance
LeMaitre Vascular is a specialized provider of medical devices, implants, and services used primarily in the treatment of peripheral vascular disease — a condition affecting arteries and veins outside the heart. The company develops and markets a portfolio of roughly twelve branded product lines, including grafts, shunts, and catheters, distributed across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. In recent quarters, LMAT has demonstrated impressive operational momentum. Third-quarter 2025 sales reached $61 million, reflecting 11% reported growth and 12% organic growth, with gross margins expanding to over 70% on an adjusted basis. The company's cash reserves swelled to $343 million, giving it considerable financial flexibility. Full-year 2025 revenue guidance pointed to approximately $248 million, representing 13% organic growth. In 2026, the stock has surged roughly 28% year-to-date, rebounding from late-2025 softness and reflecting investor confidence in the company's disciplined execution, international expansion — particularly the Artegraft product launch — and steadily improving profitability.
SYK Overview and Recent Performance
Stryker Corporation is a global medical technology leader operating across three primary segments: MedSurg and Neurotechnology, Orthopaedics, and Spine. Its expansive product portfolio encompasses surgical equipment, robotic-assisted surgery platforms such as Mako, joint replacement implants, neurovascular devices, and emergency medical equipment. Stryker closed full-year 2025 with reported revenue of $25.1 billion, representing 11.2% growth and 10.3% organic expansion. Adjusted EPS (earnings per share) rose 11.8% to $13.63. The company entered 2026 with strong procedural volume trends and guided for 8.0% to 9.5% organic sales growth. However, the year has presented unexpected challenges. A cyberattack in the first quarter of 2026 disrupted operations and contributed to an earnings miss that weighed heavily on investor sentiment. As a result, SYK shares have been essentially flat year-to-date and remain well below their all-time high of approximately $405 reached in mid-2025. The stock's beta (a measure of volatility relative to the broader market) of 0.78 underscores its historically defensive character, but the cyber incident has introduced near-term uncertainty.
Trending AI Robots
For traders seeking an analytical edge in comparing stocks like LMAT and SYK, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to navigate shifting market conditions. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only a select group earns placement in the Trending AI Robots section — those that demonstrate the most promising alignment with current market dynamics. These bots employ Financial Learning Models (FLMs), an advanced integration of machine learning algorithms with technical analysis, and span a wide array of trading styles including trend following, swing trading, and day trading across multiple timeframes from 5-minute to daily charts. Performance metrics vary considerably across bots, with some top-performing strategies posting annualized returns exceeding 70% and success rates above 75% in profitable trades during recent periods. Each bot operates with distinct parameters — different sets of tickers, position sizing rules, risk management protocols, and strategy logic — giving users the flexibility to match an AI approach to their specific trading objectives. Explore the Trending AI Robots page to discover which strategies are currently resonating with real-time market data.
Head-to-Head Comparison
The most immediate contrast between these two stocks lies in their scale and market positioning. Stryker generated $25.1 billion in revenue in 2025 — more than 100 times LeMaitre's $248 million. This vast difference shapes nearly every comparative dimension. Stryker's diversified portfolio across orthopaedics, surgical technologies, neurotechnology, and medical equipment gives it multiple growth engines and significant resilience against single-product headwinds. LMAT's focused niche in peripheral vascular devices, by contrast, means its fortunes are more tightly linked to procedural volumes and product adoption within a more concentrated market.
On growth, both companies have posted compelling numbers. LMAT's organic growth rate of 12-13% has been modestly ahead of Stryker's 9-11% range, though off a far smaller base. Margin profiles also differ: LMAT's adjusted gross margins of roughly 70% and operating margins approaching 28% reflect the high-value, specialized nature of its vascular product lines, while Stryker's adjusted operating margin of 26.3% in 2025 represents steady improvement driven by pricing initiatives and easing cost pressures across a far more complex manufacturing footprint.
Risk factors present another meaningful divergence. Stryker's exposure to hospital capital budgets, its reliance on large-scale manufacturing and global supply chains, and its vulnerability to cybersecurity threats were all underscored by the Q1 2026 cyberattack. LMAT, with a leaner organization of approximately 655 employees and a simpler operational structure, has fewer external attack surfaces. Sentiment-wise, LMAT's upward trend in 2026 reflects a market rewarding consistent execution, while Stryker's sideways price action suggests investors are waiting for clearer evidence that the cyber incident's effects are fully behind the company.
Tickeron AI Verdict
Based on observable market data and trend patterns, Tickeron's AI-driven analysis would likely express a near-term preference for LMAT over SYK. LMAT's price action in 2026 has exhibited greater trend consistency, with the stock steadily climbing from approximately $80 at the start of the year toward $104 in late July, supported by clean quarterly results and upward earnings revisions. Its low beta of 0.52 suggests that this advance has been achieved without excessive volatility — a hallmark of institutional accumulation rather than speculative churn. Stryker, while fundamentally sound with a strong 2026 growth outlook, continues to trade under the shadow of the Q1 cyberattack and carries less favorable short-term momentum. The AI would likely recognize Stryker's long-term quality and diversified revenue base as attractive features, but would tilt toward LMAT on the basis of cleaner trend signals, superior recent momentum, and fewer unresolved operational overhangs. As always, this probabilistic assessment reflects current conditions and is subject to change as new data emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LMAT is a Hold and SYK is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LMAT’s FA Score shows that 2 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- LMAT’s FA Score: 2 green, 3 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LMAT’s TA Score shows that 5 TA indicator(s) are bullish while SYK’s TA Score has 6 bullish TA indicator(s).
- LMAT’s TA Score: 5 bullish, 5 bearish.
- SYK’s TA Score: 6 bullish, 4 bearish.
Price Growth
LMAT (@Pharmaceuticals: Other) experienced а +5.99% price change this week, while SYK (@Medical/Nursing Services) price change was -1.38% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.03%. For the same industry, the average monthly price growth was +0.09%, and the average quarterly price growth was -1.71%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.50%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -17.67%.
Reported Earning Dates
LMAT is expected to report earnings on Aug 04, 2026.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+5.03% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (+2.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| LMAT | SYK | LMAT / SYK | |
| Capitalization | 2.32B | 125B | 2% |
| EBITDA | 96.3M | 6.44B | 1% |
| Gain YTD | 25.531 | -6.833 | -374% |
| P/E Ratio | 37.25 | 37.70 | 99% |
| Revenue | 256M | 25.3B | 1% |
| Total Cash | 367M | N/A | - |
| Total Debt | 190M | 14.7B | 1% |
LMAT | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 17 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 33 | 64 | |
SMR RATING 1..100 | 54 | 56 | |
PRICE GROWTH RATING 1..100 | 48 | 53 | |
P/E GROWTH RATING 1..100 | 63 | 82 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYK's Valuation (10) in the Medical Specialties industry is in the same range as LMAT (17). This means that SYK’s stock grew similarly to LMAT’s over the last 12 months.
LMAT's Profit vs Risk Rating (33) in the Medical Specialties industry is in the same range as SYK (64). This means that LMAT’s stock grew similarly to SYK’s over the last 12 months.
LMAT's SMR Rating (54) in the Medical Specialties industry is in the same range as SYK (56). This means that LMAT’s stock grew similarly to SYK’s over the last 12 months.
LMAT's Price Growth Rating (48) in the Medical Specialties industry is in the same range as SYK (53). This means that LMAT’s stock grew similarly to SYK’s over the last 12 months.
LMAT's P/E Growth Rating (63) in the Medical Specialties industry is in the same range as SYK (82). This means that LMAT’s stock grew similarly to SYK’s over the last 12 months.
| LMAT | SYK | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 65% | 4 days ago 34% |
| Stochastic ODDS (%) | 3 days ago 64% | 3 days ago 61% |
| Momentum ODDS (%) | 3 days ago 62% | 3 days ago 51% |
| MACD ODDS (%) | 3 days ago 75% | 3 days ago 73% |
| TrendWeek ODDS (%) | 3 days ago 70% | 3 days ago 52% |
| TrendMonth ODDS (%) | 3 days ago 67% | 3 days ago 47% |
| Advances ODDS (%) | 5 days ago 69% | 5 days ago 56% |
| Declines ODDS (%) | 3 days ago 53% | 3 days ago 52% |
| BollingerBands ODDS (%) | 3 days ago 78% | 3 days ago 63% |
| Aroon ODDS (%) | 3 days ago 75% | 3 days ago 47% |
Advertisement
LMAT and
Correlation & Price change
A.I.dvisor indicates that over the last year, LMAT has been loosely correlated with ITGR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if LMAT jumps, then ITGR could also see price increases.
| Ticker / NAME | Correlation To LMAT | 1D Price Change % | ||
|---|---|---|---|---|
| LMAT | 100% | -0.85% | ||
| ITGR - LMAT | 48% Loosely correlated | +20.18% | ||
| SYK - LMAT | 46% Loosely correlated | -6.42% | ||
| UFPT - LMAT | 44% Loosely correlated | -0.10% | ||
| AORT - LMAT | 40% Loosely correlated | -3.04% | ||
| RDNT - LMAT | 39% Loosely correlated | +1.74% | ||
More | ||||
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.